MetaVia Hits Top Doses of 48 mg and 64 mg in Phase 1 Obesity Trial
MTVA•MetaVia reported all 16 active patients in its Phase 1 Part 3 obesity trial completed dose titration to highest target doses of 48 mg in cohort A and 64 mg in cohort B. The company said it remains on track to report topline data by Q4 2026.
1. Dose Titration Completion
All enrolled active patients in Part 3 of MetaVia’s Phase 1 obesity study successfully escalated to their highest target doses, with cohort A reaching 48 mg and cohort B reaching 64 mg of DA-1726, reinforcing the therapy’s tolerability profile.
2. Trial Structure and Regimens
Part 3A of the trial utilized a single-step regimen of 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B employed a two-step escalation of 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks; approximately 20 subjects per part were randomized 4:1 (16 active; 4 placebo).
3. Objectives and Endpoints
The study is evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of DA-1726, with primary endpoints tracking adverse events and secondary and exploratory measures including weight change, waist circumference, glycemic control, lipid profiles and body composition.
4. Upcoming Topline Data
MetaVia plans to report topline results in Q4 2026, aiming to build on prior Phase 1 MAD data that demonstrated a 9.1% mean weight loss at 48 mg over 8 weeks and differentiated metabolic benefits versus leading GLP-1 therapies.
